Tyra Biosciences grants 44,400 stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Tyra Biosciences director Habib J. Dable received a grant of stock options covering 44,400 shares of common stock at an exercise price of $35.12 per share. The options expire on April 15, 2036 and vest monthly in 36 equal installments starting after April 16, 2026, contingent on continued service.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 44,400 | $0.00 | $0.00 |
Footnotes (1)
- F1. 1/36th of the total number of shares of common stock subject to the option vest monthly following April 16, 2026, the date of grant, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
Key Figures
Key Terms
Stock Option (Right to Buy) financial
exercise price financial
expiration date financial
vesting financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Tyra Biosciences (TYRA) report for Habib J. Dable?
What is the exercise price and expiration date of Habib J. Dable’s Tyra Biosciences options?
How do the Tyra Biosciences (TYRA) options granted to Habib J. Dable vest?
Is Habib J. Dable’s Tyra Biosciences Form 4 transaction a market buy or sell?
What does the Form 4 tell investors about Habib J. Dable’s holdings in Tyra Biosciences (TYRA)?
AI-generated analysis. How Rhea-AI works. Not financial advice.